Neoadjuvant and Adjuvant Toripalimab and Cetuximab in Patients With Recurrent, Resectable Squamous Cell Carcinoma of Head and Neck: a Prospective, Single-arm,Phase II Study

This study is the first clinical study of Neoadjuvant and Adjuvant treatment of head and neck squamous cell carcinoma with drugs targeting EGFR signaling pathway combined with PD-1 inhibitors, which explores the new combination therapies urgently needed in clinical practice and lays a foundation for subsequent studies, with important scientific research significance and clinical value.

Head and neck cancer is the sixth most common cancer in the world, with more than 550,000 incidences and 300,000 deaths worldwide each year. more than 95% of head and neck cancers are squamous cell carcinomas, and head and neck squamous cell carcinoma (HNSCC) damages and affects patients' appearance and basic physiological, sensory and speech functions, thereby affecting their quality of life. This affects the quality of life of patients. Due to the difficulty of early detection, more than 60% of head and neck squamous cell carcinoma patients are found to be locally advanced, and the prognosis of locally advanced head and neck cancer is poor, with up to 60% of patients experiencing local recurrence and distant metastasis. Currently, the preferred treatment option for patients with locally recurrent resectable HNSCC is to undergo salvage surgery with or without postoperative local radiotherapy based on pathology, staging, and history of prior radiotherapy. However, even after receiving aggressive treatment, at least 20% of patients with HNSCC still develop local recurrence or distant metastases. In previous studies, the five-year survival rates of patients with locally recurrent, resectable head and neck squamous carcinoma who underwent salvage surgery ranged from 11% to 40%. How to improve the prognosis of patients with locally recurrent, resectable HNSCC is an urgent clinical problem. The epidermal growth factor receptor (EGFR) is highly expressed in 90% of HNSCC, and high expression of EGFR protein and high copy number of its gene are significantly associated with poor prognosis, short survival, and increased risk of metastasis in HNSCC. The chimeric EGFR-blocking monoclonal antibody cetuximab is approved by the FDA for the first/second-line treatment of recurrent/metastatic, unresectable HNSCC and significantly improves long-term survival in recurrent/metastatic, unresectable HNSCC compared with chemotherapy alone. In the 2021 edition of the CSCO guidelines, cetuximab is recommended as a Class I expert in combination with chemotherapy for the first-line treatment of recurrent/metastatic HNSCC without indications for surgery and radiotherapy (Class 1A evidence), and as a Class II expert in single-agent use for the second-line or salvage treatment of recurrent/metastatic HNSCC without indications for surgery and radiotherapy (Class 2A evidence). Meanwhile, it was approved by the CFDA in February 2020 in combination with platinum and fluorouracil chemotherapy for the first-line treatment of recurrent/metastatic HNSCC, and was successfully covered by Medicare in November 2021. However, whether cetuximab provides a survival benefit in patients with locally recurrent, resectable HNSCC has not been reported in studies. The successful development of programmed death receptor 1 (PD-1) immune checkpoint inhibitors has significantly impacted the treatment of HNSCC. In patients with unresectable recurrent or metastatic HNSCC resistant to platinum-based therapy, KEYNOTE-040 compared pembrolizumab with the investigator's choice of treatment regimen (docetaxel, methotrexate, or cetuximab), and this trial was just short of the primary endpoint (improved overall survival with pembrolizumab) in the intention-to-treat population (8.4 months in the pembrolizumab group \[95% CI, 6.4 to 9.4\] vs. 6.9 months \[95% CI, 5.9 to 8.0\] in the standard treatment group; hazard ratio for death, 0.80; 95% CI, 0.65 to 0.98; P=0.02). In the CheckMate 141 trial, which randomized patients who had received prior platinum-based therapy in a 2:1 ratio to receive either nivolumab or a regimen of the investigator's choice, respectively. Nivolumab improved overall survival (7.5 months \[95% CI, 5.5 to 9.1\] vs. 5.1 months \[95% CI, 4.0 to 6.0\]; hazard ratio for death, 0.70; 97.73% CI, 0.51 to 0.96; P=0.01), remission rate (13.3% vs. 5.8%) and 6-month progression-free survival (19.7% vs. 9.9%), and reduced the incidence of serious adverse events (13.1% vs. 35.1%). After more than 2 years of follow-up, a survival benefit of nivolumab treatment remained for patients (hazard ratio for death, 0.68; 95% CI, 0.54 to 0.86; 24-month overall survival, 16.9% vs. 6.0%). The U.S. Food and Drug Administration (FDA) approved both pembrolizumab and nivolumab in 2016 for second-line treatment of advanced HNSCC because they enabled patients to achieve durable remissions and improved survival. In the KEYNOTE-048 study, 882 patients with previously untreated recurrent or metastatic HNSCC were randomized to receive either pembrolizumab monotherapy, Pembrolizumab + chemotherapy (fluorouracil and platinum-based agents) or the standard treatment regimen of fluorouracil and platinum-based agents + cetuximab (the regimen in the EXTREME trial), which confirmed that In the first-line treatment of patients with unresectable recurrent or metastatic HNSCC, pembrolizumab combined with chemotherapy significantly improved overall survival in the total population, and pembrolizumab alone in those with CPS ≥ 1, compared with the traditional EXTREME regimen of targeted chemotherapy, and the FDA approved pembrolizumab for the first-line treatment of advanced HNSCC in 2019. Currently, immunotherapy and EGFR-targeted therapy for combination therapy have been explored in several studies. The basic rationale supporting these combination therapies is that the two therapies combine different immunological and tumor biological mechanisms that enhance antitumor activity; it is well known that anti-PD-1 therapy enhances cytotoxic T lymphocytes and promotes tumor regression and immune rejection. In contrast, anti-EGFR antibodies induce antibody-dependent cytotoxicity and lead to interactions between immune cells (including natural killer cells and dendritic cells). This interaction can stimulate tumor antigen-specific cellular immunity and generate antigen-specific T-lymphocyte responses \[12\]. Thus, the two classes of drugs may produce antitumor synergistic effects. In an open-label, multicenter, multicohort phase II clinical trial, the application of pembrolizumab in combination with cetuximab in 33 patients with unresectable recurrent/metastatic HNSCC not previously treated with pembrolizumab and cetuximab showed an overall response rate of 45% at 6 months, while the median duration of remission in patients with effective treatment reached 13.3 months, and two other cohorts are currently recruiting and results have not yet been published, initially showing that the combination of immunotherapy and EGFR-targeted therapy holds promise in patients with relapsed/metastatic HNSCC. However, this treatment modality has not been explored in patients with relapsed resectable HNSCC. In an open-label, multicenter, single-arm phase II clinical trial, patients with locally relapsed resectable HNSCC were treated with the PD-1 inhibitor nivolumab and the NK cell surface molecule KIR inhibitor Lirilumab in a double-exemption study that was expected to enroll 54 patients, but only 28 subjects were ultimately enrolled due to discontinuation of Lirilumab supply. The study found that the enrolled patients achieved a pathological remission rate of 43%, a one-year DFS of 55.2%, and a 2-year DFS rate of 64% and a 2-year OS rate of 80% in subjects who achieved pathological remission, possibly limited by study discontinuation of enrollment, which has shown good long-term efficacy although the primary study endpoint was not met. JS001 or toripalimab, the most leading investigational drug of Juniper Biologics against various malignancies, is a recombinant humanized anti-PD-1 injectable monoclonal antibody that was approved for marketing by the State Drug Administration (NMPA) of China on December 17, 2018.JS001 has a high binding affinity and can better compete with PD-L1 and PD-L2 binding competition on tumor cells, while inducing endocytosis of PD-1 receptors and reducing PD-1 expression on the cell membrane surface. Results from completed clinical trials of toripalimab in a variety of cancers, including malignant melanoma, nasopharyngeal carcinoma, and esophageal squamous cell carcinoma, showed that immune-related adverse events were rare and received the first global conditional approval in China on December 17, 2018, for the treatment of unresectable or metastatic melanoma that was previously unavailable for systemic therapy. Individual cases have shown excellent responsiveness and good tolerability of the combination of toripalimab and single-agent chemotherapy in the first-line treatment of elderly R/M HNSCC, while its therapeutic role in R/M HNSCC remains to be investigated. Therefore, based on the data of previously reported studies of EGFR-targeted therapy combined with immunotherapy in patients with unresectable recurrent/metastatic HNSCC and the preliminary results of PD-1 combined with KIR inhibitors in patients with locally recurrent resectable HNSCC treated with double-free neoadjuvant therapy, we hypothesized that cetuximab in combination with toripalimab prior to salvage surgery could benefit to this high-risk population of patients with locally recurrent resectable HNSCC. This study is the first clinical study of EGFR-targeted therapy combined with PD-1 inhibitor for the neoadjuvant treatment of locally recurrent resectable HNSCC in China, which is of great scientific significance and clinical value in exploring the urgent need for new combination therapies and new treatment options for this high-risk group of patients with locally recurrent resectable HNSCC, and laying the foundation for subsequent studies.